EFFICACY OF RAVULIZUMAB TREATMENT ACCORDING TO TIME FROM DIAGNOSIS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: A POST HOC SUBGROUP ANALYSIS OF THE CHAMPION MG STUDY

被引：0
|
作者：
Howard, James F., Jr. [1 ]
Vu, Tuan [2 ]
Mantegazza, Renato [3 ]
Kushlaf, Hani [4 ]
Suzuki, Shigeaki [5 ]
Wiendl, Heinz [6 ]
Beasley, Kathleen N. [7 ]
Liao, Serena [7 ]
Meisel, Andreas [8 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[3] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Keio Univ, Sch Med, Tokyo, Japan
[6] Univ Hosp Munster, Munster, Germany
[7] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[8] Charite Univ Med Berlin, Berlin, Germany
来源：
MUSCLE & NERVE | 2022年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [1] Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study
    Howard Jr, James F.
    Vu, Tuan
    Mantegazza, Renato
    Kushlaf, Hani
    Suzuki, Shigeaki
    Wiendl, Heinz
    Beasley, Kathleen N.
    Liao, Serena
    Meisel, Andreas
    MUSCLE & NERVE, 2024, 69 (05) : 556 - 565
  • [2] CONSISTENT EFFICACY OF RAVULIZUMAB ACROSS SEX AND AGE SUBGROUPS OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: A POST HOC ANALYSIS OF THE CHAMPION MG STUDY
    Juel, Vern
    Vu, Tuan
    Casasnovas, Carlos
    Uzawa, Akiyuki
    Aguzzi, Rasha
    Frick, Glen
    Howard, James F., Jr.
    MUSCLE & NERVE, 2022, 65 : S1 - S2
  • [3] Ravulizumab in adults with generalised myasthenia gravis: Post hoc analysis of MG-ADL item score change in CHAMPION MG
    Vissing, J.
    Mozaffar, T.
    Mantegazza, R.
    Attarian, S.
    Yoshimura, S.
    Beasley, K.
    Liao, S.
    Pandya, S.
    Howard, J., Jr.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 211 - 211
  • [4] Achievement of Improved Post-Intervention Status in Patients with Generalized Myasthenia Gravis Treated with Ravulizumab during the CHAMPION MG Study
    Muppidi, Srikanth
    Narayanaswami, Pushpa
    Meisel, Andreas
    Vu, Tuan
    Utsugisawa, Kimiaki
    Mantegazza, Renato
    Beasley, Kathleen
    Liao, Serena
    Howard, James
    NEUROLOGY, 2023, 100 (17)
  • [5] Ravulizumab in Adults with Generalized Myasthenia Gravis: A Sub-Analysis of the Phase 3 CHAMPION MG Study According to Chronic IVIg Use at Study Entry
    Bril, Vera
    Shin, Jin-Hong
    Silvestri, Nicholas
    Winkley, James
    Gordon, Andrew
    Suzuki, Yasushi
    Aguzzi, Rasha
    Frick, Glen
    NEUROLOGY, 2023, 100 (17)
  • [6] ROZANOLIXIZUMAB TREATMENT PATTERNS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: POST HOC ANALYSIS
    Habib, Ali A.
    Vu, Tuan
    Utsugisawa, Kimiaki
    Grosskreutz, Julian
    Sacconi, Sabrina
    Vissing, John
    Boehnlein, Marion
    Grimson, Fiona
    Pulido-Valdeolivas, Irene
    Tarancon, Thais
    Bril, Vera
    MUSCLE & NERVE, 2024, 70 (03) : 692 - 692
  • [7] ROZANOLIXIZUMAB IN PATIENTS AGED ≥65 YEARS WITH GENERALIZED MYASTHENIA GRAVIS: A POST HOC ANALYSIS OF THE PHASE 3 MYCARING STUDY
    Vu, Tuan
    Habib, Ali A.
    Pascuzzi, Robert M.
    Sacconi, Sabrina
    Grimson, Fiona
    Pulido-Valdeolivas, Irene
    Tarancon, Thais
    Bril, Vera
    MUSCLE & NERVE, 2024, 70 (03) : 612 - 613
  • [8] Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis
    Kushner, Robert F.
    Fink-Jensen, Anders
    Frenkel, Ofir
    McGowan, Barbara
    Goldman, Bryan
    Overvad, Maria
    Wadden, Thomas
    OBESITY, 2024, 32 (02) : 273 - 280
  • [9] Efficacy of Rozanolixizumab in Generalized Myasthenia Gravis: Subgroup Analyses from the Randomized Phase 3 MycarinG Study
    Vu, Tuan
    Druzdz, Artur
    Grosskreutz, Julian
    Habib, Ali A.
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vissing, John
    Beau-Lejdstrom, Raphaelle
    Boehnlein, Marion
    Gasalla, Teresa
    Grimson, Fiona
    Tarancon, Thais
    Bril, Vera
    NEUROLOGY, 2023, 100 (17)
  • [10] Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis
    Vissing, J.
    Grosskreutz, J.
    Habib, A.
    Mahuwala, Z.
    Mantegazza, R.
    Pascuzzi, R.
    Sacconi, S.
    Vu, T.
    Lejdstrom, R. Beau
    Greve, B.
    Grimson, F.
    Tarancon, T.
    Bril, V.
    NEUROMUSCULAR DISORDERS, 2024, 43
12345